TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial of Telephone Interventions for Pediatric Obesity in School Age Children
Brief Summary: In this study, we evaluate whether dietary advice based on two healthy nutritional programs can be effectively delivered to families over one month by telephone. We hypothesize that among overweight school age children, a one-month telephone intervention will result in specific dietary changes consistent with the randomly assigned dietary intervention.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: 1 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: 2 | Intervention Type: BEHAVIORAL; Name: 1; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: 2; Assigned to Arm(s): 2
B: Arm Label: LGI; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Low glycemic index diet | Arm Label: HGI; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: High glycemic index diet | Arm Label: HB; Type: EXPERIMENTAL; Interventions: Other: Home-based exercise intervention | Arm Label: CONTROL; Type: ACTIVE_COMPARATOR; Interventions: Other: Non-exercisers | Intervention Type: DIETARY_SUPPLEMENT; Name: Low glycemic index diet; Assigned to Arm(s): LGI | Intervention Type: DIETARY_SUPPLEMENT; Name: High glycemic index diet; Assigned to Arm(s): HGI | Intervention Type: OTHER; Name: Home-based exercise intervention; Assigned to Arm(s): HB | Intervention Type: OTHER; Name: Non-exercisers; Assigned to Arm(s): CONTROL
C: Intervention Type: BEHAVIORAL; Name: High and low glycemic index; Assigned to Arm(s): N/A
D: Arm Label: Low GI; Type: ACTIVE_COMPARATOR; Interventions: Other: Low GI | Arm Label: High GI; Type: EXPERIMENTAL; Interventions: Other: High GI | Intervention Type: OTHER; Name: Low GI; Assigned to Arm(s): Low GI | Intervention Type: OTHER; Name: High GI; Assigned to Arm(s): High GI

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Maintenance Oral Nifedipine for Management of Symptomatic Placenta Previa : A Randomized Clinical Trial
Brief Summary: The objective of our study is to determine the clinical utility related to the maintenance oral nifedipine therapy in patients with symptomatic placenta previa. This study is a prospective, randomized controlled trial with the inclusion, after 24 weeks gestation, of hospitalized patients with symptomatic placenta praevia. All patients may initially receive oral nifedipine therapy with steroid prophylaxis for 48 hours. After then, patients are randomly assigned to receive either oral nifedipine (20 mg every 8 hours) or placebo (one every 8 hours) until 37 weeks of gestation.

The primary outcome for the trial is the length of pregnancy in days after the enrollment. A sample size calculation is designed to detect at least a 14 -day difference in time gained in patients with maintenance oral nifedipine therapy. A sample size of about 52 patients per group would have a 80 % chance of detecting this difference at the 5 % level of significance.


Options:
A: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Nifedipine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Nifedipine; Assigned to Arm(s): B
B: Arm Label: Group one have received Transdermal nitroglycerin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Transdermal nitroglycerin | Arm Label: Group two have received nifedipine; Type: ACTIVE_COMPARATOR; Interventions: Drug: nifedipine | Intervention Type: DRUG; Name: Transdermal nitroglycerin; Assigned to Arm(s): Group one have received Transdermal nitroglycerin | Intervention Type: DRUG; Name: nifedipine; Assigned to Arm(s): Group two have received nifedipine
C: Arm Label: Indomethacin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Indomethacin | Arm Label: Nifedipine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nifedipine | Intervention Type: DRUG; Name: Indomethacin; Assigned to Arm(s): Indomethacin | Intervention Type: DRUG; Name: Nifedipine; Assigned to Arm(s): Nifedipine
D: Intervention Type: DRUG; Name: indomethacin; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Behavioral Insomnia Therapy For Those With Insomnia and Depression
Brief Summary: This study is a randomized clinical trial to test the efficacy of Cognitive-Behavioral Insomnia Therapy when used in isolation or in combination with antidepressant medication (escitalopram) among patients with Major depressive disorder and insomnia.


Options:
A: Arm Label: Trazodone; Type: EXPERIMENTAL; Interventions: Drug: Trazodone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Trazodone; Assigned to Arm(s): Trazodone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Amitriptyline; Assigned to Arm(s): N/A
C: Arm Label: milnacipran; Type: EXPERIMENTAL; Interventions: Drug: Milnacipran | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Milnacipran; Assigned to Arm(s): milnacipran | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Escitalopram + CBT-I | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: CBT-I plus placebo antidepressant medication | Arm Label: 3; Type: SHAM_COMPARATOR; Interventions: Drug: Escitalopram | Intervention Type: DRUG; Name: Escitalopram + CBT-I; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: CBT-I plus placebo antidepressant medication; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): 3

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Feasibility of Endurance Exercise Training on Cardiovascular Risk Factors Following Radical Prostatectomy Among Men With Localized Prostate Cancer; A Community-Based Intervention
Brief Summary: The primary objective is to determine the feasibility and acceptability of a home-based endurance exercise program among men diagnosed with clinically localized prostate cancer.


Options:
A: Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise Arm; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise Arm
B: Arm Label: Exercise Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Physical activity counseling | Arm Label: Contact Control; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical activity counseling; Assigned to Arm(s): Exercise Counseling
C: Intervention Type: BEHAVIORAL; Name: exercise intervention; Assigned to Arm(s): N/A | Intervention Type: GENETIC; Name: gene expression analysis; Assigned to Arm(s): N/A | Intervention Type: GENETIC; Name: polymerase chain reaction; Assigned to Arm(s): N/A | Intervention Type: GENETIC; Name: proteomic profiling; Assigned to Arm(s): N/A | Intervention Type: GENETIC; Name: reverse transcriptase-polymerase chain reaction; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: laboratory biomarker analysis; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: medical chart review; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: questionnaire administration; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: psychosocial assessment and care; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: support group therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: therapeutic dietary intervention; Assigned to Arm(s): N/A
D: Arm Label: 1: exercise with 2 counseling types; Type: EXPERIMENTAL; Interventions: Behavioral: Experimental 1: exercise with 2 counseling types | Arm Label: 2. Usual Care - written materials; Type: OTHER; Interventions: Other: Usual Care - written materials | Intervention Type: BEHAVIORAL; Name: Experimental 1: exercise with 2 counseling types; Assigned to Arm(s): 1: exercise with 2 counseling types | Intervention Type: OTHER; Name: Usual Care - written materials; Assigned to Arm(s): 2. Usual Care - written materials

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind, Placebo-controled Parallel Group Efficacy and Safety Study of BI 1356 (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug Naive or Previously Treated (6 Weeks Washout) Type 2 Diabetic Patients With Insufficient Glycemic Control
Brief Summary: To investigate efficacy, safety and tolerability of BI 1356 versus placebo


Options:
A: Arm Label: Canagliflozin 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin, Drug: Metformin immediate release | Arm Label: Canagliflozin 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin, Drug: Metformin immediate release | Arm Label: Sitagliptin 100 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sitagliptin, Drug: Metformin immediate release | Arm Label: Placebo/Sitagliptin; Type: OTHER; Interventions: Drug: Placebo, Drug: Sitagliptin, Drug: Metformin immediate release | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/Sitagliptin | Intervention Type: DRUG; Name: Canagliflozin; Assigned to Arm(s): Canagliflozin 100 mg, Canagliflozin 300 mg | Intervention Type: DRUG; Name: Sitagliptin; Assigned to Arm(s): Placebo/Sitagliptin, Sitagliptin 100 mg | Intervention Type: DRUG; Name: Metformin immediate release; Assigned to Arm(s): Canagliflozin 100 mg, Canagliflozin 300 mg, Placebo/Sitagliptin, Sitagliptin 100 mg
B: Arm Label: linagliptin 5 mg; Type: EXPERIMENTAL; Interventions: Drug: linagliptin | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: linagliptin; Assigned to Arm(s): linagliptin 5 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: linagliptin 5 mg; Type: EXPERIMENTAL; Interventions: Drug: linagliptin | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: linagliptin; Assigned to Arm(s): linagliptin 5 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: Vildagliptin & metformin; Type: EXPERIMENTAL; Interventions: Drug: Vildagliptin, Drug: Metformin | Arm Label: Glibenclamide & metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glibenclamide, Drug: Metformin | Intervention Type: DRUG; Name: Vildagliptin; Assigned to Arm(s): Vildagliptin & metformin | Intervention Type: DRUG; Name: Glibenclamide; Assigned to Arm(s): Glibenclamide & metformin | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Glibenclamide & metformin, Vildagliptin & metformin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Gene Expression in Adipose Tissue of Genes Involved in Obesity, Insulin Resistance and Lipid Metabolism Before and After Weight Loss or an Intensive Exercise Period
Brief Summary: Lifestyle and genetic factors interact in the development of obesity and the metabolic syndrome. The molecular mechanisms underlying the beneficial dietary modifications are, however, unclear. We aimed to examine the effect of the long-term 30 moderate weight reduction on gene expression in adipose tissue (AT) and to identify genes and gene clusters responsive to treatment and thereby likely contributing to the development of the metabolic syndrome. Thus, randomized controlled and individualized weight reduction and physical exercise intervention was conducted. In the WR group, glucose metabolism improved that was not seen in other groups. Moreover, an inverse correlation between the change in SI and the change in body weight was found (r =-0.44, p=0.026). Down-regulation of gene expression (p\<0.01) involving gene ontology groups of extracellular matrix, cell death was seen. Such changes did not occur in the other groups.


Options:
A: Arm Label: Intensive therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle consultation: weight control, diet, exercise | Arm Label: Conventional therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lifestyle consultation: weight control, diet, exercise | Intervention Type: BEHAVIORAL; Name: Lifestyle consultation: weight control, diet, exercise; Assigned to Arm(s): Intensive therapy | Intervention Type: BEHAVIORAL; Name: Lifestyle consultation: weight control, diet, exercise; Assigned to Arm(s): Conventional therapy
B: Arm Label: Lifestyle on-line intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle on-line intervention | Intervention Type: BEHAVIORAL; Name: Lifestyle on-line intervention; Assigned to Arm(s): Lifestyle on-line intervention
C: Intervention Type: BEHAVIORAL; Name: Weight reduction, Resistance training, Aerobic exercise training, Control; Assigned to Arm(s): N/A
D: Arm Label: eHealth weight loss intervention; Type: EXPERIMENTAL; Interventions: Behavioral: eHealth weight loss intervention | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: eHealth weight loss intervention; Assigned to Arm(s): eHealth weight loss intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Gene Expression in Adipose Tissue of Genes Involved in Obesity, Insulin Resistance and Lipid Metabolism Before and After Weight Loss or an Intensive Exercise Period
Brief Summary: Lifestyle and genetic factors interact in the development of obesity and the metabolic syndrome. The molecular mechanisms underlying the beneficial dietary modifications are, however, unclear. We aimed to examine the effect of the long-term 30 moderate weight reduction on gene expression in adipose tissue (AT) and to identify genes and gene clusters responsive to treatment and thereby likely contributing to the development of the metabolic syndrome. Thus, randomized controlled and individualized weight reduction and physical exercise intervention was conducted. In the WR group, glucose metabolism improved that was not seen in other groups. Moreover, an inverse correlation between the change in SI and the change in body weight was found (r =-0.44, p=0.026). Down-regulation of gene expression (p\<0.01) involving gene ontology groups of extracellular matrix, cell death was seen. Such changes did not occur in the other groups.


Options:
A: Intervention Type: BEHAVIORAL; Name: diet, sodium-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: exercise; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, reducing; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: alcohol drinking; Assigned to Arm(s): N/A
B: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Other: Weight loss intervention | Arm Label: Control Group (delayed intervention); Type: EXPERIMENTAL; Interventions: Other: Weight loss intervention | Intervention Type: OTHER; Name: Weight loss intervention; Assigned to Arm(s): Control Group (delayed intervention), Intervention Group
C: Intervention Type: BEHAVIORAL; Name: Weight reduction, Resistance training, Aerobic exercise training, Control; Assigned to Arm(s): N/A
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Caloric Restriction; Type: OTHER; Interventions: Behavioral: behavioral dietary intervention | Arm Label: Exercise Intervention; Type: OTHER; Interventions: Behavioral: Exercise intervention | Arm Label: Caloric Restriction AND Exercise Intervention; Type: OTHER; Interventions: Behavioral: behavioral dietary intervention, Behavioral: Exercise intervention | Intervention Type: BEHAVIORAL; Name: behavioral dietary intervention; Assigned to Arm(s): Caloric Restriction, Caloric Restriction AND Exercise Intervention | Intervention Type: BEHAVIORAL; Name: Exercise intervention; Assigned to Arm(s): Caloric Restriction AND Exercise Intervention, Exercise Intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A RCT to Evaluate the Effect of Normal Saline in 5% Dextrose at Maintenance Rate, N/5 Saline in 5% Dextrose at 2/3 Maintenance Rate and N/5 Saline in 5% Dextrose at Maintenance Rate on Incidence of Hyponatremia in Hospitalized Children.
Brief Summary: Hyponatraemia arises in between 20% and 45% of sick hospitalized children. An important reason for this high incidence could be use of hypotonic fluids in sick children for maintenance fluid therapy. There are no randomized controlled trials to evaluate the effect of various types of intravenous fluids on the incidence of hyponatremia in sick hospitalized children.

Hypothesis: Use of normal saline in 5% dextrose or reduced (2/3) volume of N/5 saline in 5% dextrose reduces incidence of hyponatremia (serum sodium 130 mmol/L) by two-thirds when compared to N/5 saline in 5% dextrose at standard maintenance rate in hospitalized children receiving intravenous maintenance fluids.


Options:
A: Arm Label: Isotonic fluid group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Isotonic fluid | Arm Label: Fluid restriction group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hypotonic fluid | Arm Label: Hypotonic fluid group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hypotonic fluid | Intervention Type: DRUG; Name: Isotonic fluid; Assigned to Arm(s): Isotonic fluid group | Intervention Type: DRUG; Name: Hypotonic fluid; Assigned to Arm(s): Fluid restriction group | Intervention Type: DRUG; Name: Hypotonic fluid; Assigned to Arm(s): Hypotonic fluid group
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: 0.9% saline in 5% dextrose (intravenous) | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: 0.45% saline in 5% dextrose (intravenous) | Intervention Type: DRUG; Name: 0.9% saline in 5% dextrose (intravenous); Assigned to Arm(s): A | Intervention Type: DRUG; Name: 0.45% saline in 5% dextrose (intravenous); Assigned to Arm(s): B
C: Arm Label: 0.9% NaCl; Type: EXPERIMENTAL; Interventions: Drug: 0.9% NaCl | Arm Label: 0.45% NaCl; Type: ACTIVE_COMPARATOR; Interventions: Drug: 0.45%NaCl | Intervention Type: DRUG; Name: 0.9% NaCl; Assigned to Arm(s): 0.9% NaCl | Intervention Type: DRUG; Name: 0.45%NaCl; Assigned to Arm(s): 0.45% NaCl
D: Arm Label: Hypotonic; Type: ACTIVE_COMPARATOR; Interventions: Drug: hypotonic | Arm Label: Isotonic; Type: EXPERIMENTAL; Interventions: Drug: isotonic | Intervention Type: DRUG; Name: hypotonic; Assigned to Arm(s): Hypotonic | Intervention Type: DRUG; Name: isotonic; Assigned to Arm(s): Isotonic

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Use Of Lorazepam For The Treatment Of Pediatric Status Epilepticus: A Randomized, Double-Blinded Trial Of Lorazepam And Diazepam
Brief Summary: Children with seizures are frequently seen in the emergency department. The drug lorazepam, which is commonly used, is not labeled by the US Food and Drug Administration for children for this use. The FDA, under the Best Pharmaceuticals for Children Act, has requested that a study comparing diazepam, a drug that is labeled by the FDA for this indication, with lorazepam be performed. The study will show whether one drug is more effective and safe than the other.


Options:
A: Arm Label: 1 drug; Type: ACTIVE_COMPARATOR; Interventions: Drug: Diclofenac, Paracetamol, Ibuprofen | Arm Label: 2 drug; Type: PLACEBO_COMPARATOR; Interventions: Drug: Diclofenac, Paracetamol, Ibuprofen | Arm Label: 3 drug; Type: ACTIVE_COMPARATOR; Interventions: Drug: Diclofenac, Paracetamol, Ibuprofen | Arm Label: 4 drug; Type: ACTIVE_COMPARATOR; Interventions: Drug: Diclofenac, Paracetamol, Ibuprofen | Arm Label: 5 drug; Type: PLACEBO_COMPARATOR; Interventions: Drug: Diclofenac, Paracetamol, Ibuprofen | Intervention Type: DRUG; Name: Diclofenac, Paracetamol, Ibuprofen; Assigned to Arm(s): 1 drug, 2 drug, 3 drug, 4 drug, 5 drug
B: Arm Label: Cohort 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: lorazepam or diazepam | Arm Label: Cohort 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: lorazepam or diazepam | Intervention Type: DRUG; Name: lorazepam or diazepam; Assigned to Arm(s): Cohort 1, Cohort 2
C: Arm Label: Intranasal Midazolam 0.2mg/kg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Midazolam | Arm Label: Rectal Diazepam 0.3-0.5 mg/kg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Diazepam | Intervention Type: DRUG; Name: Midazolam; Assigned to Arm(s): Intranasal Midazolam 0.2mg/kg | Intervention Type: DRUG; Name: Diazepam; Assigned to Arm(s): Rectal Diazepam 0.3-0.5 mg/kg
D: Intervention Type: DRUG; Name: intranasal lorazepam; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: intramuscular paraldehyde; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Ceftriaxone, With Adjunctive Clarithromycin, in the Treatment of Adult Subjects With Community-Acquired Pneumonia
Brief Summary: The purpose of this study is to determine whether ceftaroline is effective and safe in the treatment of Community-Acquired Pneumonia


Options:
A: Arm Label: Rapid result; Type: EXPERIMENTAL; Interventions: Procedure: Access to diagnostic test | Arm Label: Delayed result; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Access to diagnostic test; Assigned to Arm(s): Rapid result
B: Arm Label: Levofloxacin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Levofloxacin | Arm Label: CEM-101; Type: EXPERIMENTAL; Interventions: Drug: CEM-101 | Intervention Type: DRUG; Name: Levofloxacin; Assigned to Arm(s): Levofloxacin | Intervention Type: DRUG; Name: CEM-101; Assigned to Arm(s): CEM-101
C: Arm Label: Ceftaroline fosamil for injection; Type: EXPERIMENTAL; Interventions: Drug: Ceftaroline fosamil for Injection | Arm Label: IV Ceftriaxone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ceftriaxone, Drug: Placebo | Intervention Type: DRUG; Name: Ceftaroline fosamil for Injection; Assigned to Arm(s): Ceftaroline fosamil for injection | Intervention Type: DRUG; Name: Ceftriaxone; Assigned to Arm(s): IV Ceftriaxone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): IV Ceftriaxone
D: Arm Label: Ceftaroline fosamil for Injection; Type: EXPERIMENTAL; Interventions: Drug: Ceftaroline fosamil for Injection, Drug: Clarithromycin | Arm Label: IV Ceftriaxone; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV Ceftriaxone, Drug: Placebo, Drug: Clarithromycin | Intervention Type: DRUG; Name: Ceftaroline fosamil for Injection; Assigned to Arm(s): Ceftaroline fosamil for Injection | Intervention Type: DRUG; Name: IV Ceftriaxone; Assigned to Arm(s): IV Ceftriaxone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): IV Ceftriaxone | Intervention Type: DRUG; Name: Clarithromycin; Assigned to Arm(s): Ceftaroline fosamil for Injection, IV Ceftriaxone

Answer: D